Copper that cancer with lysosomal love!

Zaklina Kovacevic, Sumit Sahni, Des Richardson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There is now extensive evidence that chelation of copper and/or iron can inhibit tumour growth in cell culture, animal models and human clinical trials. These effects are due to the essential role these metal ions play in a variety of biological processes, including DNA synthesis. As such, there is growing interest in the development of new agents that surpass the anti-tumor activity of traditional metal-binding drugs such as desferrioxamine (DFO). Since entering this field over 20 years ago, our laboratory has been particularly interested in novel aroylhydrazones, and more recently thiosemicarbazones, that bind iron and copper and inhibit tumor growth in vitro and in vivo. Our team have pioneered the development of a new class of agents, known as the di-2-pyridylketone thiosemicarbazones (DpT analogues) that show marked and selective anti-tumour activity.
Original languageEnglish
Pages (from-to)210-211
Number of pages2
JournalAging
Volume8
Issue number2
Publication statusPublished - 2016

Fingerprint Dive into the research topics of 'Copper that cancer with lysosomal love!'. Together they form a unique fingerprint.

  • Cite this

    Kovacevic, Z., Sahni, S., & Richardson, D. (2016). Copper that cancer with lysosomal love! Aging, 8(2), 210-211.